DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

Information source: Pfizer
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute Coronary Syndrome

Intervention: Dalteparin (Drug)

Phase: N/A

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

To collect data on safety and effectiveness of dalteparin in the management of non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without percutaneous corornary intervention [PCI] or coronary artery bypass graft [CABG] within 48 hours).

Clinical Details

Official title: Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome:

Number of Participants With Death or Myocardial Infarction (MI)

Number of Participants With Major Bleeding Events

Number of Participants With Minor Bleeding Events

Detailed description: t

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female patients of 18 years or more presenting with chest pain will be

potentially eligible for inclusion in the study if they satisfy the criteria for unstable coronary artery disease per the investigator's routine practice and have received at least one injection of Fragmin (dalteparin sodium) as part of routine clinical practice and is expected to be treated conservatively (without PCI or CABG within 48 hours) during the index hospitalization.

- Evidence of a personally signed and dated informed consent document indicating that

the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria:

- Patients who are contraindicated to receive this agent per the local approved

prescribing information.

Locations and Contacts

Pfizer Investigational Site, Ahmedabad, Gujarat 380 051, India

Pfizer Investigational Site, Surat, Gujarat 395004, India

Pfizer Investigational Site, Hissar, Haryana 125 001, India

Pfizer Investigational Site, Hissar, Haryana 125005, India

Pfizer Investigational Site, Bangalore, Karnataka 562114, India

Pfizer Investigational Site, Manglore, Karnataka 575 018, India

Pfizer Investigational Site, Mysore, Karnataka 570 020, India

Pfizer Investigational Site, Nagpur, Maharahtra 440017, India

Pfizer Investigational Site, Nashik, Maharahtra 3, India

Pfizer Investigational Site, Ambernath (E), Maharashtra 421501, India

Pfizer Investigational Site, Nagpur, Maharashtra 440 010, India

Pfizer Investigational Site, Nagpur, Maharashtra 440012, India

Pfizer Investigational Site, Nagpur, Maharashtra 440033, India

Pfizer Investigational Site, Nagpur, Maharashtra 440 001, India

Pfizer Investigational Site, Nashik Road, Maharashtra 422 101, India

Pfizer Investigational Site, Nashik Road, Maharashtra 422 002, India

Pfizer Investigational Site, Nashik, Maharashtra 422 002, India

Pfizer Investigational Site, Nashik, Maharashtra 422 009, India

Pfizer Investigational Site, Thane, Maharashtra, India

Pfizer Investigational Site, Bikaner, Rajasthan 334003, India

Pfizer Investigational Site, Jaipur, Rajasthan 302 012, India

Pfizer Investigational Site, Jaipur, Rajasthan 302019, India

Pfizer Investigational Site, Chennai, Tamil Nadu 600 035, India

Pfizer Investigational Site, Kolkata, West Bengal 700 019, India

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: May 2009
Last updated: January 19, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017